Clinical Trial

A Phase 1b Study of GKL-006 Injection in Patients With Unresectable Hepatocellular Carcinoma

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a Phase 1b study of GKL-006 Injection in patients with unresectable hepatocellular carcinoma.
Trial Details
NCT Number NCT07713290
Lead Sponsor Beijing Gene Key Life Technology Co., Ltd
Conditions Hepatocellular Carcinoma (HCC), Unresectable Hepatocellular Cancer
Enrollment 6 participants
Start Date 2025-04-03
Primary Completion 2026-11-12 (estimated)
Study Completion 2027-02-28 (estimated)
Updated on ClinicalTrials.gov 2026-07-20